Navigation Links
Cord Blood America Says 2009 Debt Reduction Tops $10 Million
Date:12/16/2009

LAS VEGAS, Dec. 16 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com ) focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, said today that it has reduced its debt by a total of $1.4 million so far in the fourth quarter of 2009 and total debt eliminated for the year now tops $10 million.

"We said going into this year that reducing debt, and subsequently strengthening our balance sheet, would be a very high priority," said Matthew Schissler, co-founder and CEO. "With more than $10 million in debt retired, we succeeded in this goal and are very pleased to make this announcement to our shareholders."

Cord Blood America recently announced a grand opening of its stem cell laboratory and headquarters in Las Vegas on January 22, 2010. "We can salute this financial achievement as we open perhaps the largest cryogenic storage facility in the U.S.," Mr. Schissler said.

About Cord Blood America

Cord Blood America (OTC Bulletin Board: CBAI) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTC Bulletin Board: CBAI), visit our website at www.corcell.com. For investor information, visit www.cordblood-america.com.


        CONTACT:
        Paul Knopick
        E & E Communications
        949/707-5365
        pknopick@eandecommunications.com

Forward-Looking Statements

Some statements made in this press release are forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We use words such as "anticipate,'' "believe,'' "expect,'' "future,'' "intend,'' "plan,'' and similar expressions to identify forward-looking statements. These statements including those related to the growth of the industry, new stem cell treatments, and the Company's performance, are only predictions and are subject to certain risks, uncertainties and assumptions. Additional risks are identified and described in the Company's public filings with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.

SOURCE Cord Blood America, Inc.


'/>"/>
SOURCE Cord Blood America, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Diabetics: 3tailer Partners with MyGlucoHealth on World's 1st Blood Glucose Meter with Wireless Bluetooth for Diabetes
2. Regado Biosciences Announces Allowance in Europe of a Fundamental Patent Broadly Covering Oligonucleotide Modulators to Blood Coagulation Factor Aptamers
3. Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure
4. Childrens Hospital in Colorado Rounds off List of 24 Cord Blood Transplant Centers Worldwide Enrolling for ExCell Trial Studying StemEx(R) for Leukemia and Lymphoma
5. QIAGENs New Product Line, QIAsafe(R) DNA Blood, has Been Co-Developed With Biomatrica and is Based on Biomatricas SampleMatrix(R) Technology
6. BloodStor(TM) Stem Cell Biopreservation Media Platform Launched by BioLife Solutions
7. Cord Blood America Announces Preferred Pricing for Blue Cross of Northeastern Pennsylvania Members
8. MRI simulation of blood flow helps plan childs delicate heart surgery
9. Bayers CONTOUR and Bayers BREEZE2 Blood Glucose Monitoring Systems Do Not Use Problematic GDH-PQQ Technology
10. Fenwal and Golden Meditech Agree to Form Joint Venture in China for Blood Collection and Transfusion Technologies
11. Cord Blood America New Las Vegas Stem Cell Laboratory Scheduled for Opening in 4th Quarter 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... ... August 15, 2017 , ... Nanomedical Diagnostics ... biotherapeutics development, announces the launch of the new NHS Agile biosensor chip ... binding data for a wide range of molecules, including small and large molecules, ...
(Date:8/15/2017)... ... August 15, 2017 , ... Kenall, a ... downlights designed to stay tightly sealed and perform efficiently for years. The downlights ... location listings just aren't enough, such as: hospitals; behavioral health facilities; cleanrooms; containment ...
(Date:8/15/2017)... ... August 15, 2017 , ... JULABO USA introduces its new ... website makes it easy to navigate through the site whether you’re in the ... product information, educational industry content and visit the company’s social media accounts, all ...
(Date:8/14/2017)... New York, NY (PRWEB) , ... August 14, 2017 , ... ... Mobile in Clinical Trials event, which will take place on September 6, 2017 ... Daniel Karlin, MD , Head of Experimental Medicine, Informatics, and Regulatory Strategy, Pfizer ...
Breaking Biology Technology:
(Date:3/27/2017)... 2017  Catholic Health Services (CHS) has been ... (HIMSS) Analytics for achieving Stage 6 on the ... In addition, CHS previously earned a place in ... electronic medical record (EMR). "HIMSS Analytics ... EMR usage in an outpatient setting.  This recognition ...
(Date:3/23/2017)... India , March 23, 2017 The report "Gesture ... Touchless Biometric), Industry, and Geography - Global Forecast to 2022", published by MarketsandMarkets, ... at a CAGR of 29.63% between 2017 and 2022. ... ... ...
(Date:3/22/2017)... March 21, 2017 Optimove , ... by retailers such as 1-800-Flowers and AdoreMe, today ... Recommendations and Replenishment. Using Optimove,s machine learning algorithms, ... product and replenishment recommendations to their customers based ... predictions of customer intent drawn from a complex ...
Breaking Biology News(10 mins):